Product Information

Commercial Vaccine Products

Influenza (Flu) - The Chinese Centers for Disease Control & Prevention (CDCs) recommends immunizing against influenza as soon as the vaccine becomes available. China Biopharma’s flu vaccine, approved by the Chinese State Food and Drug Administration (SFDA) for distribution, is among the first to be delivered and made available to the general public in China for the 2006-2007 Flu Season. Through its manufacturing joint venture partner, Zhejiang Tianyuan Biopharma Co., the Company began shipping its first batch of flu vaccines to local CDCs, the Xi’an Social Security Pension Fund Program, insurance companies and hospitals in August 2006. Management expects to deliver a total of three million doses by year’s end.

Epidemic Hemorrhagic Fever (EHF) – EHF is carried by rodents in Asia and causes devastating lung infections in humans. CBPC owns over 90% market share in China against this disease, and estimates it will sell one million doses of its EHF vaccine in 2006.

Epidemic Japanese Encephalitis (EJE) – EJE, the "Plague of the Orient," is the leading cause of viral encephalitis in Asia. An inflammation of the brain, EJE exists in epidemic proportions in temperate and northern tropical regions. Rates of EJE are steady and even increasing in the areas of South and Southeast Asia. (source: Public Health Agency of Canada). China Biopharma’s EJE vaccine was approved by the SFDA in December 2005 and will be available in China in early 2007.


Developing Products

Group A ,C, Y, W135 Meningococcal Polysaccharide – CPBC has successfully completed Phase III clinical trials and pending SFDA approval, the vaccine will be commercialized in early 2008.

Avian (“Bird Flu”) H5N1 Virus – By February 2004, the avian or “bird” flu spread across 10 countries in Asia and caused dozens of deaths in Thailand and Vietnam. In China, the bird flu affected more than half of all provinces and territories. CBPC stands to be a major player in creating and mass-producing a vaccine for a potential pandemic bird flu outbreak. In June 2006, China Biopharma received a copy of the H5N1 virus (a deadly virus transmitted from bird to human), and has begun animal testing on a vaccine.

Allergy vaccine – According to the American Academy of Allergy, Asthma and Immunology, 1 in 4 people suffer from an allergy worldwide. In fact, the allergy treatment and relief medicine category is growing over 10% per annum and is estimated to be an $18 billion global market. China Biopharma is developing an allergy vaccine in strategic alliance with a European allergy vaccine producer (who markets a similar vaccine in Europe) to reach the Chinese allergy market. China Biopharma will perform clinical studies, apply for SFDA registration, and retain the exclusive copyrights to market the vaccine throughout China.